20 November 2026 | Friday | News
Image Source: Public Domain
Adcendo ApS ("Adcendo"), a biotech company focused on the development of differentiated antibody-drug conjugates (ADCs) for cancers with high unmet medical need, announced initial data from the ongoing Phase 1 ADCElerate1 trial evaluating ADCE-D01, a first-in-class ADC against the novel target uPARAP, in patients with advanced soft tissue sarcoma (STS). The data were highlighted in a late-breaking oral presentation during the plenary session on clinical trials at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), taking place November 18-20 in Barcelona, Spain.
Prof. Dr. Patrick Schöffski, MPH, Head of the Department of General Medical Oncology at the University Hospitals Leuven, Professor in the Department of Oncology at KU Leuven, Belgium, and principal investigator of the ADCElerate1 trial, commented: "Advanced soft tissue sarcoma remains one of our most challenging clinical areas, where historic second-line options routinely yield response rates of only 4 – 10%. The observed 30% objective response rate and high disease control rate seen with ADCE-D01 could mark an important shift, offering a desperately needed novel therapy across STS subtypes for patients who have exhausted standard therapies."
Dr. Lone H. Ottesen MD, PhD, Chief Medical Officer of Adcendo, said: "We are extremely pleased to share the first clinical data for ADCE-D01 at ENA which demonstrate encouraging antitumor activity and disease control across multiple STS subtypes in a population with substantial unmet medical need. We believe these data point to ADCE-D01's transformative treatment potential, while also validating Adcendo's target biology and indication-driven approach to developing a pipeline of highly effective and well tolerated ADCs. Together with world leading sarcoma centers in the US and Europe, we continue to enroll patients in the ADCElerate1 study as we work to further explore ADCE-D01's potential and define the development path."
ADCE-D01 Demonstrates Compelling Antitumor Activity Across Multiple STS Subtypes
Among the 27 response-evaluable patients representing 12 different STS subtypes who received ADCE-D01 every 2 weeks (Q2W), 8 patients had a partial response (PR) for an objective response rate of 30% (5 confirmed, 3 currently unconfirmed), and the disease control rate was 85% (23/27). A trend towards improved efficacy at higher dose levels was observed. Median follow-up was 3.4 months, and the median duration of response had not yet been reached. At data cutoff, all responses were ongoing and 81% (22/27) of evaluable patients remained on treatment.
ADCE-D01 Demonstrates Manageable Safety and Tolerability
47 adults with advanced STS including 17 different subtypes, who had received prior systemic treatment including chemotherapy and targeted agents (a median of two prior lines of therapy [range 1-4]) were enrolled into the study. The first 18 patients received ADCE-D01 on a weekly dosing schedule at a dose of 0.5–3.4 mg/kg. After establishing that dosing Q2W was more suitable due to the pharmacokinetics observed on the weekly dosing schedule, the next 29 patients were dosed at 3.4-5.5 mg/kg Q2W. All patients receiving more than 3.4 mg/kg were also given prophylactic treatment with granulocyte colony-stimulating factor (G-CSF).
The most common treatment-related side effects on the Q2W schedule were low-grade nausea (59%), infusion related reactions (41%), tiredness (38%), and hair loss (35%). The most common hematological side effect was neutropenia (31%). On the Q2W schedule, side effects led to a dose reduction in 10% of patients, and no patients needed to discontinue treatment for side effects. With prophylactic G-CSF, severe (grade 3 or higher) neutropenia occurred in 14% (3/22) of patients, compared with 43% (3/7) of patients without prophylactic G-CSF, even though the patients given G-CSF were receiving higher doses. The maximum tolerated dose (MTD) for the Q2W regimen has not yet been reached. No cases of interstitial lung disease, febrile neutropenia or stomatitis were observed.
Recruitment on the Q2W schedule is ongoing. ADCE-D01 has received Fast Track and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of STS.
© 2026 Biopharma Boardroom. All Rights Reserved.